In this episode, the editorial team spoke with Dr. Brett Wingeier, CEO of neuromodulation MedTech Magnus Medical, about the company’s Magnus System for the treatment of major depressive disorder (MDD). The neurostimulation device received breakthrough device designation from the US Food and Drug Administration (FDA) last month. The team heard from Dr. Wingeier about the challenges of treating depression and how neuromodulation shows clinical effectiveness in treating the condition. Given this, he explained how the company decided to develop the Magnus System and described how it works. As a 20-year veteran in the field of neuromodulation, hear Dr. Wingeier’s insights into how the field has grown over the last two decades and its continuing growth in the future.
Read the full article here:
Subscribe to the Xtalks Life Science Podcast to never miss a new episode.